Caspofungin
| Clinical data | |
|---|---|
| Pronunciation | /ˌkæspoʊˈfʌndʒɪn/ KAS-poh-FUN-jin |
| Trade names | Cancidas |
| Other names | (4R,5S)-5-[(2-Aminoethyl)amino]-N2-(10,12-dimethyltetradecanoyl)- 4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6→1)-peptide : 185 1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine] pneumocandin B0 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615001 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 100% (intravenous use only) |
| Protein binding | ~97% |
| Metabolism | Peptide hydrolysis, N-acetylation |
| Elimination half-life | 9–11 hours |
| Excretion | Kidney (41%), feces (35%) |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI | |
| ChEMBL |
|
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C52H88N10O15 |
| Molar mass | 1093.331 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
| (what is this?) | |
Caspofungin (INN; brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc. It is a member of a class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall.
Caspofungin was the first inhibitor of fungal (1→3)-β-D-glucan synthesis to be approved by the United States Food and Drug Administration. Caspofungin is administered intravenously. It is on the World Health Organization's List of Essential Medicines.